Subjects | Yungjin signed a collaborative research agreement with Curome for treatment of rare mitochondrial disease | hit | 1347 |
---|---|---|---|
Write | R&D | Date | 2021-09-13 |
Yungjin Pharm. Co., Ltd. (CEO, Chae J. Lee, ¡°Yungjin¡±)
announced on July 26th, 2021 that the company has signed a
collaborative research & development agreement with Curome BioSciences(CEO,
Jooseong. Yoon, ¡°Curome¡±) to develop drug for the treatment of rare and
incurable mitochondrial diseases. This agreement was made to create synergy in
the treatment field of rare and incurable diseases from early screening stage,
drug candidate discovery, clinical studies to commercialization by integrating
the two companies¡¯ mitochondria-related source technologies, patents and
know-how. Yungjin has been focusing on drug
development for genetic mitochondrial diseases since its acquisition of
KT&G Life Sciences. In 2017, Yungjin out-licensed ¡®KL1333¡¯, a drug
candidate for mitochondrial disease, to Abliva. Recently, Abliva successfully completed
clinical phase 1a/b study with KL1333 in the UK. From the clinical results, Abliva
reported positive pharmacokinetic data as well as signs of efficacy in patients
with mitochondrial diseases. In addition, there was an association between
levels of KL1333 in the patients and efficacy. No serious adverse events were
observed in the study. Based on such results, Abliva and Yungjin aim to develop
KL1333 as the first-in-class drug for mitochondrial diseases and globally
commercialize in 2024. ¡°The successful results from KL1333 phase
1a/b study provide us with a great opportunity for expanding indication such as
rare and incurable diseases. This collaborative research with Curome will
integrate both companies¡¯ mitochondria-related source technologies, Yungjin¡¯s
capability for global clinical development, business and commercialization,
establishing Yungjin as a global leader in mitochondrial medicine.¡± says
Yungjin¡¯s CEO, Chae J. Lee. Curome is a bio-venture company developing therapies for rare and incurable diseases. The company holds mitochondria study results and patents. Curome is leading mitochondrial function research in Korea cooperating with Chungnam National University College of Medicine and Korea Research Institute of Bioscience and Biotechnology that have been focusing on this field. |